Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?
AlloVir, Inc. (ALVR) closed the last trading session at $7.65, gaining 9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...
AlloVir, Inc. (ALVR) closed the last trading session at $7.83, gaining 45.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
NEW YORK, March 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AlloVir, Inc.. Shareholders who purchased shares of ALVR during the class period listed are ...
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ: ALVR ...
According to the complaint, in March 2022, AlloVir initiated global phase 3 registrational studies of its lead product posoleucel for the prevention of life-threatening viral infections from viruses ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AlloVir, Inc. (ALVR) been one of those stocks this year? A ...
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AlloVir ...
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the posoleucel Phase 3 Studies were ...
ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR WHY: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results